COVID-19 ACTUALIZACION. Nueva variante, nuevas terapias, vacunas para niños

David| Gaus

David| Gaus Andean Health and Development

Palabras clave: Covid-19, actualización noviembre 2021, guía clínica

Resumen

Se realiza una actualización del conocimiento medico científico sobre el COVID-19 en relación, a la epidemiologia, factores de riesgo y comorbilidades, fisiopatología, utilidad de los exámenes de imagen, tratamiento, y vacunas

Descargas

La descarga de datos todavía no está disponible.

Citas

1. Imran M, Arora M, Asdaq S, et al. Discovery, development, and patent trends on molnupiravir: a prospective oral treatment for COVID-19. Molecules. 2021, 26;5795. https://mdpi-res.com/molecules/molecules-26-05795/article_deploy/molecules-26-05795.pdf
2. Fischer, W.; Eron, J.; Holman, W.; Cohen, M.S.; Fang, L.; Szewczyk, L.J.; Sheahan, T.P.; Baric, R.; Mollan, K.R.; Wolfe, C.R.; et al. Molnupiravir, an Oral Antiviral Treatment for COVID-19. medRxiv 2021.
3. Merck news release. Merck and Ridgeback’s investigational oral antiviral molnupiravir reduced the risk of hospitalizacion or death by approximately 50 percent compared to placebo for pateints with mild or moderate COVID-19 in positive interim analysis of phase 3 study. Oct 1, 2021. https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/
4. Robbins R. Merck says it has the first antiviral pill found to be effective against Covid. New York Times. 27 Oct 2021. https://www.nytimes.com/2021/10/01/business/covid-antiviral-pill-merck.html?campaign_id=154&emc=edit_cb_20211027&instance_id=43967&nl=coronavirus-briefing®i_id=162851164&segment_id=72840&te=1&user_id=9aa1585711e7638a66b0dab788c44d8e
5. Merck news release. Merck, Ridgeback Biotherapeutics and Emory University will not receive royalties for sales of molnupiravir under this agreement for as long as COVID-19 remains classified as a public health emergency of international concern by the WHO. 27 Oct 2021. https://www.merck.com/news/the-medicines-patent-pool-mpp-and-merck-enter-into-license-agreement-for-molnupiravir-an-investigational-oral-antiviral-covid-19-medicine-to-increase-broad-access-in-low-and-middle-income-countri/
6. Hensley S. Pfizer-BioNTech COVID vaccine appears more than 90% effective in kids 5 to 11. NPR news. 22 oct 2021. https://www.npr.org/sections/health-shots/2021/10/22/1048334791/pfizer-biontech-covid-vaccine-appears-more-than-90-effective-in-kids-5-to-11
7. Neel J. FDA advisory panel recommends Pfizer vaccine for kids ages 5 to 11. NPR news. 26 oct 2021. https://www.npr.org/sections/health-shots/2021/10/26/1049372524/fda-panel-recommends-pfizer-vaccine-for-kids-ages-5-to-11
8. Neel J. 26 oct 2021
9. Han B, Song Y, Li C, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccines (Coronavac) in healthy children and adolescents: a double blind, randomized, controlled, phase ½ clinical trial. The Lancet Inf Dis. Published on line 28 June 2021. DOI: https://doi.org/10.1016/S1473-3099(21)00319-4
10. Shrank W, Patrick A, Brookhart M. Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. J Gen Intern Med. 2011 May;26(5):546-50 doi: 10.1007/s11606-010-1609-1.
11. Análisis de la efectividad de la vacunación frente a COVID-19 en España https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/covid19/docs/Efectividad_VacunacionCOVID-19_Espana.pdf
12. Kershner I. Israel will require a booster shot to be considered fully vaccinates. New York Times. 21 oct 2021. https://www.nytimes.com/2021/10/03/world/israel-covid-booster.html
13. Browett A. COVID-19 Situation Update. Johns Hopkins. 4 Nov 2021. https://mail.google.com/mail/u/0/#search/hopkis/FMfcgzGlkjcZzKBtsgTBlwHZVxwJsGbf